Update 03.17.2017: The good news indeed came 7 days later.
Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate. [Read more]
Here is the chart on the news:
This post is pure fun speculation. Originally posted to InvestorVillage ABUS board.
Good news brewing in the chart
Pure speculation here on the tight flat pattern and potential reverse triangle pattern.
The RNAi world is changed: I feel it in the ABUS, I feel it in the ALNY, I smell it in the ARWR and DRNA…Much that once was is lost, for none now live who remember it.
It will be either cohort 3 eAg+ patients data; or Moderna IP settlement.
Current low volume range bound is going to break out, most likely upwards with the general biotech sector IBB/XBI.
Just my humble wishful thinking. I don’t think it’s going to be range bound for years as the other thread suggests. Sentiment and expectation are so low on this board ([email protected]) and twitter, except for this post 🙂